EJNMMI Radiopharmacy and Chemistry is a peer-reviewed journal focusing on the development of new imaging and radionuclide-based therapeutic agents for nuclear medicine and molecular...
The field of radionuclide therapeutics, production, and radiochemistry is at a pivotal juncture, marked by rapid advancements with significant implications for patient care. Recent breakthroughs in Peptide Receptor Radionuclide Therapy (PRRT) and PSMA-targeted radiopharmaceuticals illustrate the potential for personalised medicine, which enhances treatment efficacy while minimising healthy tissue exposure. Furthermore, innovations in radionuclide synthesis and automation are facilitating the efficient production of high-purity radiopharmaceuticals, addressing the urgent need for effective therapies as cancer incidence rises globally. It is crucial to foster collaborative research to evaluate these innovations and ensure consistent regulatory frameworks, ultimately improving patient outcomes. By addressing safety and ethical considerations, we can enhance public trust in radionuclide therapies. The future promises more advanced treatments, driven by better tumour biology understanding and novel delivery systems. We invite researchers to contribute to this Collection, exploring significant advancements that can redefine clinical practice in oncology.
Submit your manuscript to this collection through the participating journal.
-
Jens Pietzsch
Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.Jens Pietzsch is a biochemist and radiopharmacologist; he earned his doctorate in 1996 from the Technical University of Dresden, specializing in medical biochemistry and internal medicine. He heads the Department of Radiopharmaceutical and Chemical Biology at the Institute of Radiopharmaceutical Cancer Research at the Helmholtz-Zentrum Dresden-Rossendorf and serves as Professor of Pathological Biochemistry/Medical Biochemistry at the Faculty of Chemistry and Food Chemistry at the Technical University of Dresden. His research focuses on targeted, radionuclide-based theranostics for solid, treatment-resistant malignant tumors, including rare cancers and pediatric malignancies. His work centers primarily on preclinical studies to characterize new radioligands using dedicated multimodal small-animal imaging techniques.
-
R. Michael van Dam
David Geffen School of Medicine at University of California Los Angeles, Los Angeles, United States.R. Michael van Dam, Ph.D. is a Professor in the Department of Molecular & Medical Pharmacology at the University of California, Los Angeles, Associate Director of the Crump Institute for Molecular Imaging, and Director of the Crump Cyclotron and Radiochemistry Technology Center.
His research focuses on developing novel technologies to increase access to radiopharmaceuticals (e.g., PET imaging tracers and theranostic agents), including microscale approaches for multi-step radiosynthesis, high-throughput methods for radiopharmaceutical development, and high-sensitivity techniques for radiochemical analysis. He has published over 90 papers and book chapters, and has been granted nearly 30 patents, related to these discoveries.
Dr. van Dam was a co-founder of Sofie, Inc., which commercialized the ELIXYS FLEX/CHEM and PURE/FORM radiosynthesis platform based on technology and control software developed in his laboratory. He is also a co-founder of DropletPharma Corp, which is commercializing the microscale droplet-based technologies his lab developed for radiopharmaceutical development and production.
He received his B.Sc. in Engineering Physics from Queen's University (Kingston, ON, Canada), M.A.Sc. in Computer Engineering from the University of Toronto (Toronto, ON, Canada), and Ph.D. in Applied Physics from the California Institute of Technology (Pasadena, CA, USA).
